{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:04:36Z","timestamp":1750831476791,"version":"3.37.3"},"reference-count":23,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology (DST), Govt. of India","doi-asserted-by":"publisher","award":["SR\/PURSE Phase 2\/15 (G)","10.04.2018"],"award-info":[{"award-number":["SR\/PURSE Phase 2\/15 (G)","10.04.2018"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Breast cancer is one of the greatest global dilemmas, and the current treatment\noption is to target hormone receptors with partial agonists\/antagonists. Estrogen and aromatase enzymes\nplay important roles in breast cancer. Excessive estrogen activity or inadequate estrogen production leads\nto various hormonal issues, including breast cancer. Potent breast cancer drugs are Tamoxifen, Paclitaxel,\nCyclophosphamide, Trastuzumab, etc., and aromatase inhibitors, include Anastrozole, Letrozole, and Exemestane,\netc. In general, breast cancer drugs cause numerous adverse effects in humans.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>This study has attempted to identify alternative drug candidates from Carica papaya for treating\nbreast cancer with fewer side effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>To achieve this, we have utilized computational methods to predict the characteristics of bioactive\ncompounds from Carica papaya and determine the target binding affinities using the Schr\u00f6dinger suite\n(Maestro 9.5). The target protein and ligands were obtained from the well-known database. Carica papaya\nhas 35 identified bioactive compounds that were drawn using ChemDraw software and performed Ligand\npreparation wizard. Absorption, Distribution, Metabolism, and Excretion (ADME) analysis is performed\nwith QikProp.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>From the docking studies, the phytocompounds such as Chlorogenic acid, Myricetin, Quercetin,\nIsorhamnetin, and Catechin showed the highest Glide scores (G Score). Among the five bioactive phytocompounds,\nChlorogenic acid has a higher G Score with good binding energy than Tamoxifen, Anastrozole,\nand Letrozole standards. The pharmacokinetic properties and drug-likeness of phytocompounds were\ndetermined using ADME profiling.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Carica papaya phytocompounds serve as an antiestrogen or aromatase inhibitor that regulates\nestrogen levels to reduce the risk of breast cancer in postmenopausal women. As a result, we recommend\nthat these top five bioactive phytocompounds be investigated further in in vitro and in vivo studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573409918666220519112027","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T12:57:40Z","timestamp":1653224260000},"page":"196-212","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In silico Approach and Molecular Docking Studies of Potent Bioactive Compounds\nof Carica papaya as Anti-breast Cancer Agents"],"prefix":"10.2174","volume":"18","author":[{"given":"Sankaran","family":"Mirunalini","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Chidambaram-608 002, Tamil Nadu,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.L.","family":"Maruthanila","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Chidambaram-608 002, Tamil Nadu,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramakrishnan","family":"Elancheran","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Annamalai University, Annamalainagar, Chidambaram-608 002, Tamil Nadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"15743","DOI":"10.1038\/s41598-019-52162-0","volume":"9","author":"Acharya R.","year":"2019","unstructured":"Acharya R.; Chacko S.; Bose P.; Lapenna A.; Pattanayak S.P.; Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Sci Rep 2019,9(1),15743","journal-title":"Sci Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12282-016-0732-1","volume":"24","author":"Maruthanila V.L.","year":"2017","unstructured":"Maruthanila V.L.; Elancheran R.; Kunnumakkara A.B.; Kabilan S.; Kotoky J.; Recent development of targeted approaches for the treat-ment of breast cancer. Breast Cancer 2017,24(2),191-219","journal-title":"Breast Cancer"},{"key":"ref=3","first-page":"1","author":"Khalil S.","year":"2019","unstructured":"Khalil S.; Hatch L.; Price C.R.; Palakurty S.H.; Simoneit E.; Radisic A.; Pargas A.; Shetty I.; Lyman M.; Couchot P.; Roetzheim R.; Addressing breast cancer screening disparities among uninsured and insured patients: A student-run free clinic initiative. J Community Health 2019,1-5","journal-title":"J Community Health"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10799893.2018.1468780","volume":"38","author":"Sudha A.","year":"2018","unstructured":"Sudha A.; Srinivasan P.; Kanimozhi V.; Palanivel K.; Kadalmani B.; Antiproliferative and apoptosis-induction studies of 5-hydroxy 3\u2032,4\u2032,7-trimethoxyflavone in human breast cancer cells MCF-7: An in vitro and in silico approach. J Recept Signal Transduct Res 2018,38(3),179-190","journal-title":"J Recept Signal Transduct Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev.nutr.22.111401.144957","volume":"22","author":"Ross J.A.","year":"2002","unstructured":"Ross J.A.; Kasum C.M.; Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002,22(1),19-34","journal-title":"Annu Rev Nutr"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2174\/0929867023369790","volume":"9","author":"Voskresensky O.N.","year":"2002","unstructured":"Voskresensky O.N.; Levitsky A.P.; QSAR aspects of flavonoids as a plentiful source of new drugs. Curr Med Chem 2002,9(14),1367-1383","journal-title":"Curr Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.2174\/1389557520666200811102622","author":"Maruthanila V.L.","year":"2020","unstructured":"Maruthanila V.L.; Elancheran R.; Mirunalini S.; Carica papaya leaves and cancer prevention: An overview. Mini Rev Med Chem 2020","journal-title":"Mini Rev Med Chem"},{"key":"ref=8","first-page":"89","volume":"15","author":"Maruthanila V.L.","year":"2019","unstructured":"Maruthanila V.L.; Elancheran R.; Roy N.K.; Bhattacharya A.; Kunnumakkara A.B.; Kabilan S.; Kotoky J.; in silico molecular modeling of selected natural ligands and their binding features with estrogen receptor alpha. Curr. Comput. Aided. Drug Des 2019,15(1),89-96","journal-title":"Drug Des"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13065-018-0472-8","volume":"12","author":"Sharma D.","year":"2018","unstructured":"Sharma D.; Kumar S.; Narasimhan B.; Estrogen alpha receptor antagonists for the treatment of breast cancer: A review. Chem Cent J 2018,12(1),107","journal-title":"Chem Cent J"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.22159\/ijpps.2016.v8i9.12074","volume":"8","author":"Chellam J.","year":"2016","unstructured":"Chellam J.; Rohini Deepa I.; Computational biological study of aromatase inhibitors docking with human placental aromatase cytochrome P450. Int J Pharm Pharm Sci 2016,8(7),93-97","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1039\/c7tx00184c","volume":"6","author":"van Duursen M.B.M.","year":"2017","unstructured":"van Duursen M.B.M.; Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women\u2019s health. Toxicol Res (Camb) 2017,6(6),772-794","journal-title":"Toxicol Res (Camb)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.3390\/molecules16053597","volume":"16","author":"Suvannang N.","year":"2011","unstructured":"Suvannang N.; Nantasenamat C.; Isarankura-Na-Ayudhya C.; Prachayasittikul V.; Molecular docking of aromatase inhibitors. Molecules 2011,16(5),3597-3617","journal-title":"Molecules"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/01.COT.0000289796.64219.5c","volume":"28","author":"Goodman A.","year":"2006","unstructured":"Goodman A.; Extended letrozole after 5 years of tamoxifen adds benefits in hormone-receptor positive breast cancer, is cost-effective. Oncol Times 2006,28(1),6-8","journal-title":"Oncol Times"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4103\/0971-5851.171530","volume":"36","author":"Smyth L.","year":"2015","unstructured":"Smyth L.; Hudis C.; Adjuvant hormonal therapy in premenopausal women with breast cancer. Indian J Med Paediatr Oncol 2015,36(4),195-200","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/fonc.2019.00510","volume":"9","author":"El Sayed R.","year":"2019","unstructured":"El Sayed R.; El Jamal L.; El Iskandarani S.; Kort J.; Abdelsalam M.; Assi H.I.; Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: Sequencing treatment and overcoming resistance. Front Oncol 2019,9,510","journal-title":"Front Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/j.1742-1241.2007.01587.x","volume":"61","author":"Fabian C.J.","year":"2007","unstructured":"Fabian C.J.; The what, why and how of aromatase inhibitors: Hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract 2007,61(12),2051-2063","journal-title":"Int J Clin Pract"},{"key":"ref=17","first-page":"1756","volume":"17","author":"Elancheran R.","year":"2017","unstructured":"Elancheran R.; Saravanan K.; Divakar S.; Kumari S.; Maruthanila V.L.; Kabilan S.; Ramanathan M.; Devi R.; Kotoky J.; Design, syn-thesis and biological evaluation of novel 1, 3-thiazolidine-2, 4-diones as anti-prostate cancer agents. Anticancer Agents Med Chem 2017,17(13),1756-1768","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2105-15-S11-S4","volume":"15","author":"Ng H.W.","year":"2014","unstructured":"Ng H.W.; Zhang W.; Shu M.; Luo H.; Ge W.; Perkins R.; Tong W.; Hong H.; Competitive molecular docking approach for predicting estrogen receptor subtype \u03b1 agonists and antagonists. BMC Bioinformatics 2014,15(11)(Suppl. 11),S4","journal-title":"BMC Bioinformatics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10637-015-0240-8","volume":"33","author":"Singh P.","year":"2015","unstructured":"Singh P.; Bast F.; Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and andro-gen receptor; in silico and in vitro. Invest New Drugs 2015,33(3),575-593","journal-title":"Invest New Drugs"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/10428199609054801","volume":"23","author":"Larocca L.M.","year":"1996","unstructured":"Larocca L.M.; Teofili L.; Maggiano N.; Piantelli M.; Ranelletti F.O.; Leone G.; Quercetin and the growth of leukemic progenitors. Leuk Lymphoma 1996,23(1-2),49-53","journal-title":"Leuk Lymphoma"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1016\/j.bmcl.2013.06.022","volume":"23","author":"Li X.Y.","year":"2013","unstructured":"Li X.Y.; He B.F.; Luo H.J.; Huang N.Y.; Deng W.Q.; 3-Acyl-5-hydroxybenzofuran derivatives as potential anti-estrogen breast cancer agents: A combined experimental and theoretical investigation. Bioorg Med Chem Lett 2013,23(16),4617-4621","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"35401","DOI":"10.1039\/C9RA04759J","volume":"9","author":"Shtaiwi A.","year":"2019","unstructured":"Shtaiwi A.; Adnan R.; Khairuddean M.; Khan S.U.; Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer. RSC Advances 2019,9(61),35401-35416","journal-title":"RSC Advances"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1021\/acsomega.0c00352","volume":"5","author":"Zhang F.","year":"2020","unstructured":"Zhang F.; Zhai T.; Haider S.; Liu Y.; Huang Z.J.; Synergistic effect of chlorogenic acid and caffeic acid with fosfomycin on growth inhibi-tion of a resistant Listeria monocytogenes strain. ACS Omega 2020,5(13),7537-7544","journal-title":"ACS Omega"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409918666220519112027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205016\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409918666220519112027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T15:54:49Z","timestamp":1667922889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205016\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409918666220519112027","relation":{},"ISSN":["1573-4099"],"issn-type":[{"type":"print","value":"1573-4099"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}